217 related articles for article (PubMed ID: 36378541)
21. Distinct transcriptional programs of SOX2 in different types of small cell lung cancers.
Tenjin Y; Matsuura K; Kudoh S; Usuki S; Yamada T; Matsuo A; Sato Y; Saito H; Fujino K; Wakimoto J; Ichimura T; Kohrogi H; Sakagami T; Niwa H; Ito T
Lab Invest; 2020 Dec; 100(12):1575-1588. PubMed ID: 32801334
[TBL] [Abstract][Full Text] [Related]
22. An integrative transcriptome analysis reveals a functional role for thyroid transcription factor-1 in small cell lung cancer.
Horie M; Miyashita N; Mattsson JSM; Mikami Y; Sandelin M; Brunnström H; Micke P; Nagase T; Saito A
J Pathol; 2018 Oct; 246(2):154-165. PubMed ID: 29876935
[TBL] [Abstract][Full Text] [Related]
23. Comparative analysis of TTF-1 binding DNA regions in small-cell lung cancer and non-small-cell lung cancer.
Hokari S; Tamura Y; Kaneda A; Katsura A; Morikawa M; Murai F; Ehata S; Tsutsumi S; Ishikawa Y; Aburatani H; Kikuchi T; Miyazono K; Koinuma D
Mol Oncol; 2020 Feb; 14(2):277-293. PubMed ID: 31782890
[TBL] [Abstract][Full Text] [Related]
24. System analysis identifies distinct and common functional networks governed by transcription factor ASCL1, in glioma and small cell lung cancer.
Donakonda S; Sinha S; Dighe SN; Rao MRS
Mol Biosyst; 2017 Jul; 13(8):1481-1494. PubMed ID: 28742165
[TBL] [Abstract][Full Text] [Related]
25. Subtype-specific secretomic characterization of pulmonary neuroendocrine tumor cells.
Wang XD; Hu R; Ding Q; Savage TK; Huffman KE; Williams N; Cobb MH; Minna JD; Johnson JE; Yu Y
Nat Commun; 2019 Jul; 10(1):3201. PubMed ID: 31324758
[TBL] [Abstract][Full Text] [Related]
26. SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures.
Tlemsani C; Pongor L; Elloumi F; Girard L; Huffman KE; Roper N; Varma S; Luna A; Rajapakse VN; Sebastian R; Kohn KW; Krushkal J; Aladjem MI; Teicher BA; Meltzer PS; Reinhold WC; Minna JD; Thomas A; Pommier Y
Cell Rep; 2020 Oct; 33(3):108296. PubMed ID: 33086069
[TBL] [Abstract][Full Text] [Related]
27. POU domain transcription factor BRN2 is crucial for expression of ASCL1, ND1 and neuroendocrine marker molecules and cell growth in small cell lung cancer.
Ishii J; Sato H; Sakaeda M; Shishido-Hara Y; Hiramatsu C; Kamma H; Shimoyamada H; Fujiwara M; Endo T; Aoki I; Yazawa T
Pathol Int; 2013 Mar; 63(3):158-68. PubMed ID: 23530560
[TBL] [Abstract][Full Text] [Related]
28. Killing SCLC: insights into how to target a shapeshifting tumor.
Sutherland KD; Ireland AS; Oliver TG
Genes Dev; 2022 Mar; 36(5-6):241-258. PubMed ID: 35318269
[TBL] [Abstract][Full Text] [Related]
29. Clinical utility of immunohistochemical subtyping in patients with small cell lung cancer.
Chiang CL; Huang HC; Luo YH; Shen CI; Chao HS; Tseng YH; Chou TY; Schrump DS; Yeh YC; Chen YM
Lung Cancer; 2024 Feb; 188():107473. PubMed ID: 38232600
[TBL] [Abstract][Full Text] [Related]
30. Small cell lung cancer - news in the tumour´s biology.
Pavlíčková K; Matěj R
Cesk Patol; 2023; 59(1):18-22. PubMed ID: 37072275
[TBL] [Abstract][Full Text] [Related]
31. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data.
Rudin CM; Poirier JT; Byers LA; Dive C; Dowlati A; George J; Heymach JV; Johnson JE; Lehman JM; MacPherson D; Massion PP; Minna JD; Oliver TG; Quaranta V; Sage J; Thomas RK; Vakoc CR; Gazdar AF
Nat Rev Cancer; 2019 May; 19(5):289-297. PubMed ID: 30926931
[TBL] [Abstract][Full Text] [Related]
32. Molecular Subtypes of High-Grade Neuroendocrine Carcinoma (HGNEC): What is YAP1-Positive HGNEC?
Kawai H; Matsuoka R; Ito T; Matsubara D
Front Biosci (Landmark Ed); 2022 Mar; 27(3):108. PubMed ID: 35345340
[TBL] [Abstract][Full Text] [Related]
33. Significance of achaete-scute complex homologue 1 (ASCL1) in pulmonary neuroendocrine carcinomas; RNA sequence analyses using small cell lung cancer cells and Ascl1-induced pulmonary neuroendocrine carcinoma cells.
Kudoh S; Tenjin Y; Kameyama H; Ichimura T; Yamada T; Matsuo A; Kudo N; Sato Y; Ito T
Histochem Cell Biol; 2020 Jun; 153(6):443-456. PubMed ID: 32170367
[TBL] [Abstract][Full Text] [Related]
34. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition.
Augert A; Eastwood E; Ibrahim AH; Wu N; Grunblatt E; Basom R; Liggitt D; Eaton KD; Martins R; Poirier JT; Rudin CM; Milletti F; Cheng WY; Mack F; MacPherson D
Sci Signal; 2019 Feb; 12(567):. PubMed ID: 30723171
[TBL] [Abstract][Full Text] [Related]
35. KDM6A epigenetically regulates subtype plasticity in small cell lung cancer.
Duplaquet L; Li Y; Booker MA; Xie Y; Olsen SN; Patel RA; Hong D; Hatton C; Denize T; Walton E; Laimon YN; Li R; Jiang Y; Bronson RT; Southard J; Li S; Signoretti S; Qiu X; Cejas P; Armstrong SA; Long HW; Tolstorukov MY; Haffner MC; Oser MG
Nat Cell Biol; 2023 Sep; 25(9):1346-1358. PubMed ID: 37591951
[TBL] [Abstract][Full Text] [Related]
36. ASCL1 represses a SOX9
Olsen RR; Ireland AS; Kastner DW; Groves SM; Spainhower KB; Pozo K; Kelenis DP; Whitney CP; Guthrie MR; Wait SJ; Soltero D; Witt BL; Quaranta V; Johnson JE; Oliver TG
Genes Dev; 2021 Jun; 35(11-12):847-869. PubMed ID: 34016693
[TBL] [Abstract][Full Text] [Related]
37. ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers.
Augustyn A; Borromeo M; Wang T; Fujimoto J; Shao C; Dospoy PD; Lee V; Tan C; Sullivan JP; Larsen JE; Girard L; Behrens C; Wistuba II; Xie Y; Cobb MH; Gazdar AF; Johnson JE; Minna JD
Proc Natl Acad Sci U S A; 2014 Oct; 111(41):14788-93. PubMed ID: 25267614
[TBL] [Abstract][Full Text] [Related]
38. MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate.
Ireland AS; Micinski AM; Kastner DW; Guo B; Wait SJ; Spainhower KB; Conley CC; Chen OS; Guthrie MR; Soltero D; Qiao Y; Huang X; Tarapcsák S; Devarakonda S; Chalishazar MD; Gertz J; Moser JC; Marth G; Puri S; Witt BL; Spike BT; Oliver TG
Cancer Cell; 2020 Jul; 38(1):60-78.e12. PubMed ID: 32473656
[TBL] [Abstract][Full Text] [Related]
39. Whole-Section Landscape Analysis of Molecular Subtypes in Curatively Resected Small Cell Lung Cancer: Clinicopathologic Features and Prognostic Significance.
Hwang S; Hong TH; Kim HK; Choi YS; Zo JI; Shim YM; Han J; Chan Ahn Y; Pyo H; Noh JM; Lee HY; Kim HJ; Park S; Ahn MJ; Park K; Lee SH; Choi YL; Kim J
Mod Pathol; 2023 Jul; 36(7):100184. PubMed ID: 37054974
[TBL] [Abstract][Full Text] [Related]
40. MAX mutant small-cell lung cancers exhibit impaired activities of MGA-dependent noncanonical polycomb repressive complex.
Llabata P; Torres-Diz M; Gomez A; Tomas-Daza L; Romero OA; Grego-Bessa J; Llinas-Arias P; Valencia A; Esteller M; Javierre BM; Zhang X; Sanchez-Cespedes M
Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34493659
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
